Page 26 - Read Online

Page 276 Arroyo Seguí et al. J Transl Genet Genom 2020;4:263-77 I http://dx.doi.org/10.20517/jtgg.2020.35

in an outpatient buprenorphine/naloxone clinic. J Addict Med 2014;8:176-82.
10. Hadland SE, Bagley SM, Rodean J, Silverstein M, Levy S, et al. Receipt of timely addiction treatment and association of early medication
treatment with retention in care among youths with opioid use disorder. JAMA Pediatr 2018;172:1029-37.
11. Clay SW. Treatment of addiction in the elderly. Aging health 2010;6:177-89.
12. Kotelchuck M, Cheng ER, Belanoff C, Cabral HJ, Babakhanlou-Chase H, et al. The prevalence and impact of substance use disorder
and treatment on maternal obstetric experiences and birth outcomes among singleton deliveries in massachusetts. Matern Child Health J
2017;21:893-902.
13. Kaltenbach K, Finnegan LP. Developmental outcome of children born to methadone maintained women: a review of longitudinal studies.
Neurobehav Toxicol Teratol 1984;6:271-5.
14. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, et al. Neonatal abstinence syndrome after methadone or buprenorphine
exposure. N Engl J Med 2010;363:2320-31.
15. Schwartz RP, Gryczynski J, O’Grady KE, Sharfstein JM, Warren G, et al. Opioid agonist treatments and heroin overdose deaths in
Baltimore, Maryland, 1995-2009. Am J Public Health 2013;103:917-22.
16. Mattick RP, Breen C, Kimber J, Davoli M, Breen R, et al. Methadone maintenance therapy versus no opioid replacement therapy for
opioid dependence. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996.
17. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention
treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003;361:662-8.
18. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 2012;31:207-25.
19. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV
infection. Cochrane Database Syst Rev 2011;10:CD004145.
20. Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm 2010;16:S14-21.
21. Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities:
2003-2015 (Update). The CBHSQ report. Rockville, US: Substance Abuse and Mental Health Services Administration; 2017.
22. Potter JS, Dreifuss JA, Marino EN, Provost SE, Dodd DR, et al. The multi-site prescription opioid addiction treatment study: 18-month
outcomes. J Subst Abuse Treat 2015;48:62-9.
23. Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, et al. Long-term outcomes from the national drug abuse treatment clinical
trials network prescription opioid addiction treatment study. Drug Alcohol Depend 2015;150:112-9.
24. Jones HE, Fitzgerald H, Johnson RE. Males and females differ in response to opioid agonist medications. Am J Addict 2005;14:223-33.
25. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine,
and other frequently prescribed medications: a review. Am J Addict 2010;19:4-16.
26. Litz M, Leslie D. The impact of mental health comorbidities on adherence to buprenorphine: A claims based analysis. Am J Addict
2017;26:859-63.
27. Lo A, Kerr T, Hayashi K, Milloy MJ, Nosova E, et al. Factors associated with methadone maintenance therapy discontinuation among
people who inject drugs. J Subst Abuse Treat 2018;94:41-6.
28. Lopian KM, Chebolu E, Kulak JA, Kahn LS, Blondell RD. A retrospective analysis of treatment and retention outcomes of pregnant and/
or parenting women with opioid use disorder. J Subst Abuse Treat 2019;97:1-6.
29. Crist RC, Li J, Doyle GA, Gilbert A, Dechairo BM, et al. Pharmacogenetic analysis of opioid dependence treatment dose and dropout
rate. Am J Drug Alcohol Abuse 2018;44:431-40.
30. Crist RC, Doyle GA, Nelson EC, Degenhardt L, Martin NG, et al. A polymorphism in the OPRM1 3’-untranslated region is associated
with methadone efficacy in treating opioid dependence. Pharmacogenomics J 2018;18:173-9.
31. Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, et al. An intronic variant in OPRD1 predicts treatment outcome for opioid
dependence in African-Americans. Neuropsychopharmacology 2013;38:2003-10.
32. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, et al. ABCB1 and cytochrome P450 genotypes and phenotypes:
influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006;80:668-81.
33. Csajka C, Crettol S, Guidi M, Eap CB. Population genetic-based pharmacokinetic modeling of methadone and its relationship with the
QTc interval in opioid-dependent patients. Clin Pharmacokinet 2016;55:1521-33.
34. Levran O, Peles E, Hamon S, Randesi M, Adelson M, et al. CYP2B6 SNPs are associated with methadone dose required for effective
treatment of opioid addiction. Addict Biol 2013;18:709-16.
35. Peng S, Jiang H, Du J, Lin S, Pan S, et al. Methadone dosage and plasma levels, SNPs of OPRM1 gene and age of first drug use were
associated with outcomes of methadone maintenance treatment. Front Genet 2018;9:450.
36. Tian JN, Ho IK, Tsou HH, Fang CP, Hsiao CF, et al. UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in
methadone maintenance patients. Pharmacogenomics 2012;13:879-88.
37. Berrettini W. A brief review of the genetics and pharmacogenetics of opioid use disorders. Dialogues Clin Neurosci 2017;19:229-36.
38. Crist RC, Clarke TK, Berrettini WH. Pharmacogenetics of opioid use disorder treatment. CNS Drugs 2018;32:305-20.
39. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, et al. Buprenorphine versus methadone for opioid dependence: predictor variables
for treatment outcome. Drug Alcohol Depend 2004;75:37-45.
40. Serafini G, Adavastro G, Canepa G, De Berardis D, Valchera A, et al. The efficacy of buprenorphine in major depression, treatment-
resistant depression and suicidal behavior: a systematic review. Int J Mol Sci 2018;19:2410.
41. Toce MS, Chai PR, Burns MM, Boyer EW. Pharmacologic treatment of opioid use disorder: a review of pharmacotherapy, adjuncts, and
toxicity. J Med Toxicol 2018;14:306-22.